UCB gets rights to Synosia's SYN115 and SYN118; all rights later returned
Executive Summary
UCB Group has optioned exclusive global rights to Synosia Therapeutics Inc.'s (neurology drug candidates) SYN115 and SYN118 for non-orphan indications. Both drug candidates are in Phase II for Parkinson's disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice